从大麻素在多发性硬化症中的轶事性证据到新兴的新治疗方法。 - Suppr

Suppr

超能文献

From anecdotal evidence of cannabinoids in multiple sclerosis to emerging new therapeutical approaches.

作者信息

Bifulco M, Laezza C, Malfitano A M

出版信息

Mult Scler. 2007 Jan;13(1):133-4. doi: 10.1177/1352458506071303.

DOI:10.1177/1352458506071303

PMID:17294623

Abstract

摘要

相似文献

From anecdotal evidence of cannabinoids in multiple sclerosis to emerging new therapeutical approaches.

Mult Scler. 2007 Jan;13(1):133-4. doi: 10.1177/1352458506071303.

[Cannabinoids in multiple sclerosis -- therapeutically reasonable?].

Fortschr Neurol Psychiatr. 2005 Aug;73(8):463-9. doi: 10.1055/s-2004-830119.

[Cannabinoids in multiple sclerosis -- therapeutically reasonable?].

Fortschr Neurol Psychiatr. 2005 Dec;73(12):713-4. doi: 10.1055/s-2005-870992.

[There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].

Ugeskr Laeger. 2015 May 11;177(20):956-60.

Cannabis-based medicines in multiple sclerosis--a review of clinical studies.

Immunobiology. 2010 Aug;215(8):658-72. doi: 10.1016/j.imbio.2010.03.009. Epub 2010 Apr 7.

Cannabinoids in multiple sclerosis: urgent need for long term trials.

J Neurol Neurosurg Psychiatry. 2005 Dec;76(12):1612. doi: 10.1136/jnnp.2005.075333.

The therapeutic value of cannabinoids in MS: real or imaginary?

Mult Scler. 2004 Aug;10(4):339-40. doi: 10.1191/1352458504ms1064ed.

Cannabinoids on trial for multiple sclerosis.

Lancet Neurol. 2002 Jul;1(3):147. doi: 10.1016/s1474-4422(02)00068-6.

Cannabinoids in MS--are we any closer to knowing how best to use them?

Mult Scler. 2006 Oct;12(5):523-5. doi: 10.1177/1352458506072514.

Emerging properties of cannabinoid medicines in management of multiple sclerosis.

Trends Neurosci. 2005 May;28(5):272-6. doi: 10.1016/j.tins.2005.03.006.

引用本文的文献

Is There a New Road to Spinal Cord Injury Rehabilitation? A Case Report about the Effects of Driving a Go-Kart on Muscle Spasticity.

Diseases. 2023 Aug 22;11(3):107. doi: 10.3390/diseases11030107.

Immune-modulation and properties of absorption and blood brain barrier permeability of 1,8-naphthyridine derivatives.

J Neuroimmune Pharmacol. 2013 Dec;8(5):1077-86. doi: 10.1007/s11481-013-9494-0. Epub 2013 Oct 1.

Effects on immune cells of a new 1,8-naphthyridin-2-one derivative and its analogues as selective CB2 agonists: implications in multiple sclerosis.

PLoS One. 2013 May 1;8(5):e62511. doi: 10.1371/journal.pone.0062511. Print 2013.

G protein-coupled receptors as therapeutic targets for multiple sclerosis.

Cell Res. 2012 Jul;22(7):1108-28. doi: 10.1038/cr.2012.87. Epub 2012 Jun 5.

Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review.

BMC Neurol. 2009 Dec 4;9:59. doi: 10.1186/1471-2377-9-59.

Cannabinoids in the management of spasticity associated with multiple sclerosis.

Neuropsychiatr Dis Treat. 2008 Oct;4(5):847-53. doi: 10.2147/ndt.s3208.

Cannabinoids in health and disease.

Dialogues Clin Neurosci. 2007;9(4):413-30. doi: 10.31887/DCNS.2007.9.4/nkogan.

In vivo imaging of the endocannabinoid system: a novel window to a central modulatory mechanism in humans.

Eur J Nucl Med Mol Imaging. 2007 Nov;34(11):1719-26. doi: 10.1007/s00259-007-0505-3.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验